The global biotech and pharmaceutical sector have recorded $106 billion in merger and acquisition activity across 201 transactions so far in 2026, placing the industry on track for its strongest deal year since the pre-pandemic peak. The acceleration reflects a convergence of structural pressures that have been building for several years: an unprecedented wave of patent expiries approaching across the industry’s largest revenue generators, recovering public market valuations that are reducing the cost of equity-denominated deal components, and a pool of biotech companies that have demonstrated clinical proof-of-concept through their late-stage pipelines.

Average deal value in 2026 has climbed to $527 million per transaction, up from $365 million in 2025 — a 44% increase that reflects a deliberate shift in deal strategy among large-cap acquirers. Rather than placing bets on early-stage science, the dominant trend in this cycle is bolt-on acquisitions targeting assets that are either approved or at late Phase 2 or Phase 3 with a near-term PDUFA date. This risk preference is rational in the context of the patent cliff: companies that need to replace $10 to $20 billion in annual revenue within a five-year horizon have limited tolerance for clinical development attrition.

GSK has been among the most active acquirers. Its $10.6 billion agreement to purchase Nuvalent, announced June 9, was its third deal of the year following the $2.2 billion acquisition of RAPT Therapeutics and a transaction with 35Pharma. RAPT’s lead asset, ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase 2b development for food allergy prophylaxis, is being positioned as a potential best-in-class agent due to its once-quarterly dosing advantage over existing anti-IgE therapies. Nuvalent’s zidesamtinib and neladalkib, next-generation ROS1 and ALK inhibitors for NSCLC, each carry FDA Breakthrough Therapy designations and PDUFA dates in September and November 2026 respectively.

Beyond GSK, deal activity has been broad-based across therapeutic areas and company sizes. Licensing and partnership agreements — which do not appear in M&A tallies — have also expanded, providing additional evidence of pipeline demand. EY’s annual biotech analysis characterised the current environment as one in which both volume and value of deals are increasing simultaneously, a combination that typically indicates a genuine acceleration rather than a small number of outlier transactions inflating headline figures.

For smaller biotechs, the active M&A environment has translated into improved financing conditions and more credible exit pathways. The convergence of deal-hungry large-cap acquirers and clinical-stage companies with maturing assets is creating the conditions for what several analysts have described as the sector’s best year for deal activity since before the COVID-era biotech boom.

The second half of 2026 is expected to sustain this pace, with several large-cap companies that have not yet made major moves reportedly evaluating targets.